(Q37979160)

26 August 2017

mTOR inhibitors and its role in the treatment of head and neck squamous cell carcinoma (English)

1 reference

head and neck squamous cell carcinoma

26 August 2017

0 references

author name string

Shaun A Nguyen

1

1 reference

26 August 2017

David Walker

2

1 reference

26 August 2017

M Boyd Gillespie

3

1 reference

26 August 2017

J Silvio Gutkind

4

1 reference

26 August 2017

Terry A Day

5

1 reference

26 August 2017

1 March 2012

1 reference

Current Treatment Options in Oncology

26 August 2017

1 reference

26 August 2017

13

1 reference

26 August 2017

1

1 reference

26 August 2017

71-81

1 reference

https://scigraph.springernature.com/pub.10.1007/s11864-011-0180-2

26 August 2017

0 references

cites work

Defining the role of mTOR in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

The biology and clinical relevance of the PTEN tumor suppressor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

mTOR: from growth signal integration to cancer, diabetes and ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

Amino acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by rapamycin, and is independent of S6K1 and rpS6 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

A novel conditional Akt 'survival switch' reversibly protects cells from apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

Pharmacokinetics of sirolimus (rapamycin) in subjects with severe hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0180-2

Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII)

21 January 2018

1 reference

12 December 2020

Cancer statistics, 2010

1 reference

12 December 2020

Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control

1 reference

12 December 2020

Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin)

1 reference

12 December 2020

10.1007/S11864-011-0180-2

Identifiers

DOI

1 reference

26 August 2017

1 reference